Journal
CELLS
Volume 11, Issue 23, Pages -Publisher
MDPI
DOI: 10.3390/cells11233911
Keywords
human papillomavirus (HPV); cervical cancer (CC); major histocompatibility complex (MHC); The Cancer Genome Atlas (TCGA); gene expression; T cell
Categories
Funding
- Canadian Institutes of Health Research
- [PJT-173496]
Ask authors/readers for more resources
This study compared the gene expression differences between HPV-positive and HPV-negative cervical cancer and identified crucial differences in antigen presentation within the tumor immune microenvironments. These differences may contribute to the altered patient outcomes and responses to immunotherapy observed between these distinct cancers.
Cervical cancer (CC) is the second most common cancer in women worldwide and the fourth leading cause of cancer-associated death in women. Although human papillomavirus (HPV) infection is associated with nearly all CC, it has recently become clear that HPV-negative (HPV-) CC represents a distinct disease phenotype with increased mortality. HPV-positive (HPV+) and HPV- CC demonstrate different molecular pathology, prognosis, and response to treatment. Furthermore, CC caused by HPV alpha 9 types (HPV16-like) often have better outcomes than those caused by HPV alpha 7 types (HPV18-like). This study systematically and comprehensively compared the expression of genes involved in major histocompatibility complex (MHC) class I and II presentation within CC caused by HPV alpha 9 types, HPV alpha 7 types, and HPV- CC. We observed increased expression of MHC class I and II classical and non-classical genes in HPV+ CC and overall higher expression of genes involved in their antigen loading and presentation apparatus as well as transcriptional regulation. Increased expression of MHC I-related genes differs from previous studies using cell culture models. These findings identify crucial differences between antigen presentation within the tumor immune microenvironments of HPV+ and HPV- CC, as well as modest differences between HPV alpha 9 and alpha 7 CC. These differences may contribute to the altered patient outcomes and responses to immunotherapy observed between these distinct cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available